Skip to main content

Advertisement

Table 1 Baseline characteristics according to primary tumor location

From: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer

Characteristics Right colon (n = 23) Left colon and rectum (n = 147) P-value*
Age (years)    0.546
 Median (range) 57 (36–72) 55 (24–74)  
Gender    0.154
 Female 10 (43.5%) 42 (28.6%)  
 Male 13 (56.5%) 105 (71.4%)  
Stage at presentation    0.292
 Stage IV 20 (87.0%) 110 (74.8%)  
 Stage I-III 3 (13.0%) 37 (25.2%)  
Histology    0.031
 W/D or M/D 16 (80.0%) 136 (95.0%)  
 P/D or SRCC 4 (20.0%) 7 (5.0%)  
Number of metastasized organs    >0.999
 1 13 (56.5%) 81 (55.1%)  
  ≥ 2 10 (43.5%) 66 (44.9%)  
Metastasized organ    
 Liver 12 (52.2%) 106 (72.1%) 0.086
 Lung 7 (30.4%) 65 (44.2%) 0.260
 Peritoneum 6 (26.1%) 13 (8.8%) 0.026
Treatment lines    0.921
 3 16 (69.6%) 104 (70.7%)  
 4 6 (26.1%) 35 (23.8%)  
 ≥5 1 (4.3%) 8 (5.4%)  
Prior treatment
Oxaliplatin 23 (100%) 144 (98.0%) 1.00
 Bevacizumab 7 (30.4%) 25 (17.0%) 0.151
 5-fluoropyrimidine 20 (87.0%) 136 (92.5%) 0.408
Regimen    0.482
 Cetuximab + irinotecan 13 (56.5%) 97 (66.0%)  
 Cetuximab monotherapy 10 (43.5%) 50 (34.0%)  
BRAF    <0.001
 Wild-type 14 (60.9%) 139 (94.6%)  
 Mutant 9 (39.1%) 8 (5.4%)  
PIK3CA    0.018
 Wild-type 20 (87.0%) 145 (98.6%)  
 Mutant 3 (13.0%) 2 (1.4%)  
MSI status    0.156
 MSS 19 (82.6%) 85 (57.8%)  
 MSI-low 0 (0%) 3 (2.0%)  
 MSI-high 0 (0%) 1 (0.7%)  
 Not checked 4 (17.4%) 58 (39.5%)  
  1. Abbreviations: W/D well-differentiated, M/D moderately differentiated, P/D poorly differentiated, SRCC signet ring cell carcinoma, MSI microsatellite instability, MSS microsatellite stable
  2. * P-value by Fisher’s exact test or Mann-Whitney U-test as appropriate